FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129757466> ?p ?o ?g. }

• W2129757466 endingPage "188" @default.
• W2129757466 startingPage "178" @default.
• W2129757466 abstract "Clarithromycin increases both hepatic and intestinal availability of the selective cytochrome P450 (CYP) 3A probe midazolam. This study was designed to identify determinants of variability in the extent of intestinal wall CYP3A inhibition by clarithromycin, such as CYP3A5 genotype, and the mechanism of inhibition.Ten healthy volunteers received 500 mg oral clarithromycin twice a day for 7 days. Before and after administration of clarithromycin, small-bowel mucosal biopsy specimens were obtained endoscopically. Intestinal CYP3A activity was determined from the rate of 1'-hydroxymidazolam and 4-hydroxymidazolam formation by incubation of small-bowel homogenate with midazolam (25 micromol/L) and NADPH for 5 minutes. Intestinal CYP3A4 and CYP3A5 messenger ribonucleic acid was quantified by real-time reverse transcriptase-polymerase chain reaction. Intestinal CYP3A4 and CYP3A5 protein concentrations were determined by immunoblotting. Serum and homogenate concentrations of midazolam, clarithromycin, and metabolites were determined by liquid chromatography-mass spectrometry. CYP3A5 genotype was determined by real-time polymerase chain reaction.The formation of 1'-hydroxymidazolam (1.36 +/- 0.46 pmol . min(-1) . mg(-1) at baseline versus 0.35 +/- 0.16 pmol . min(-1) . mg(-1) after administration) and 4-hydroxymidazolam (0.39 +/- 0.12 pmol . min(-1) . mg(-1) at baseline versus 0.12 +/- 0.05 pmol . min(-1) . mg(-1) after administration) was significantly (P < .001) reduced after clarithromycin administration. Clarithromycin administration did not result in a significant change in intestinal CYP3A4 and CYP3A5 messenger ribonucleic acid and protein expression. All subjects had detectable serum clarithromycin concentrations after 7 days of clarithromycin (3.71 +/- 2.43 micromol/L). The mean concentration of clarithromycin in the intestinal biopsy homogenate was 1.2 +/- 0.7 nmol/L (range, 0.42-2.39 nmol/L). Compared with CYP3A5 nonexpressers, subjects with at least 1 CYP3A5*1 allele (CYP3A5 expressers) had greater inhibition of intestinal CYP3A activity after treatment with clarithromycin. There was a strong linear relationship between the decrease in intestinal CYP3A activity and baseline catalytic activity (R(2) = 0.9).Baseline intestinal activity of CYP3A4 was a key determinant of variability of the inhibitory effect of clarithromycin among individuals. CYP3A5*1 alleles were associated with greater baseline intestinal CYP3A activity and, therefore, greater extent of inhibition. The primary in vivo mechanism was not rapidly reversible competitive or irreversible inhibition but was likely formation of metabolic intermediate complexes." @default.
• W2129757466 created "2016-06-24" @default.
• W2129757466 creator A5011375614 @default.
• W2129757466 creator A5012392020 @default.
• W2129757466 creator A5014194365 @default.
• W2129757466 creator A5015098514 @default.
• W2129757466 creator A5034951559 @default.
• W2129757466 creator A5047722150 @default.
• W2129757466 creator A5055911958 @default.
• W2129757466 creator A5061090740 @default.
• W2129757466 creator A5071775392 @default.
• W2129757466 creator A5081039323 @default.
• W2129757466 date "2005-03-01" @default.
• W2129757466 modified "2023-09-24" @default.
• W2129757466 title "Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression*" @default.
• W2129757466 cites W152635832 @default.
• W2129757466 cites W1775749144 @default.
• W2129757466 cites W1894997478 @default.
• W2129757466 cites W1940970798 @default.
• W2129757466 cites W1963957404 @default.
• W2129757466 cites W1972327861 @default.
• W2129757466 cites W1978921548 @default.
• W2129757466 cites W1993544887 @default.
• W2129757466 cites W1996802313 @default.
• W2129757466 cites W1999021046 @default.
• W2129757466 cites W1999259563 @default.
• W2129757466 cites W2001344342 @default.
• W2129757466 cites W2022600795 @default.
• W2129757466 cites W2024131514 @default.
• W2129757466 cites W2043275110 @default.
• W2129757466 cites W2047031607 @default.
• W2129757466 cites W2048992861 @default.
• W2129757466 cites W2095554696 @default.
• W2129757466 cites W2097502628 @default.
• W2129757466 cites W2105902511 @default.
• W2129757466 cites W2154793110 @default.
• W2129757466 cites W2157049173 @default.
• W2129757466 cites W2158362878 @default.
• W2129757466 cites W2358501499 @default.
• W2129757466 doi "https://doi.org/10.1016/j.clpt.2004.10.002" @default.
• W2129757466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15735612" @default.
• W2129757466 hasPublicationYear "2005" @default.
• W2129757466 type Work @default.
• W2129757466 sameAs 2129757466 @default.
• W2129757466 citedByCount "56" @default.
• W2129757466 countsByYear W21297574662012 @default.
• W2129757466 countsByYear W21297574662013 @default.
• W2129757466 countsByYear W21297574662014 @default.
• W2129757466 countsByYear W21297574662015 @default.
• W2129757466 countsByYear W21297574662016 @default.
• W2129757466 countsByYear W21297574662017 @default.
• W2129757466 countsByYear W21297574662018 @default.
• W2129757466 countsByYear W21297574662019 @default.
• W2129757466 countsByYear W21297574662020 @default.
• W2129757466 countsByYear W21297574662021 @default.
• W2129757466 countsByYear W21297574662022 @default.
• W2129757466 countsByYear W21297574662023 @default.
• W2129757466 crossrefType "journal-article" @default.
• W2129757466 hasAuthorship W2129757466A5011375614 @default.
• W2129757466 hasAuthorship W2129757466A5012392020 @default.
• W2129757466 hasAuthorship W2129757466A5014194365 @default.
• W2129757466 hasAuthorship W2129757466A5015098514 @default.
• W2129757466 hasAuthorship W2129757466A5034951559 @default.
• W2129757466 hasAuthorship W2129757466A5047722150 @default.
• W2129757466 hasAuthorship W2129757466A5055911958 @default.
• W2129757466 hasAuthorship W2129757466A5061090740 @default.
• W2129757466 hasAuthorship W2129757466A5071775392 @default.
• W2129757466 hasAuthorship W2129757466A5081039323 @default.
• W2129757466 hasConcept C109650736 @default.
• W2129757466 hasConcept C11824378 @default.
• W2129757466 hasConcept C185592680 @default.
• W2129757466 hasConcept C2776814716 @default.
• W2129757466 hasConcept C2776962512 @default.
• W2129757466 hasConcept C2777056448 @default.
• W2129757466 hasConcept C2778000748 @default.
• W2129757466 hasConcept C3019249092 @default.
• W2129757466 hasConcept C501593827 @default.
• W2129757466 hasConcept C526171541 @default.
• W2129757466 hasConcept C55493867 @default.
• W2129757466 hasConcept C62231903 @default.
• W2129757466 hasConcept C86803240 @default.
• W2129757466 hasConcept C98274493 @default.
• W2129757466 hasConceptScore W2129757466C109650736 @default.
• W2129757466 hasConceptScore W2129757466C11824378 @default.
• W2129757466 hasConceptScore W2129757466C185592680 @default.
• W2129757466 hasConceptScore W2129757466C2776814716 @default.
• W2129757466 hasConceptScore W2129757466C2776962512 @default.
• W2129757466 hasConceptScore W2129757466C2777056448 @default.
• W2129757466 hasConceptScore W2129757466C2778000748 @default.
• W2129757466 hasConceptScore W2129757466C3019249092 @default.
• W2129757466 hasConceptScore W2129757466C501593827 @default.
• W2129757466 hasConceptScore W2129757466C526171541 @default.
• W2129757466 hasConceptScore W2129757466C55493867 @default.
• W2129757466 hasConceptScore W2129757466C62231903 @default.
• W2129757466 hasConceptScore W2129757466C86803240 @default.
• W2129757466 hasConceptScore W2129757466C98274493 @default.
• W2129757466 hasIssue "3" @default.
• W2129757466 hasLocation W21297574661 @default.

• next